In contrast, FOXO3a was reported to inhibit the expression β-catenin by transactivating miR-34b/c in prostate cancer [22], and FOXO3a can directly bind to β-catenin and compete with T cell factor (TCF) for the interaction to β-catenin, thereby inhibiting β-catenin/TCF transcriptional activity [23]. Here, HNF4A is linked to prostate carcinoma.